Skip Navigation

JNCI Journal of the National Cancer Institute 1994 86(3):200-209; doi:10.1093/jnci/86.3.200
© 1994 by Oxford University Press
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Goldgar, D. E.
Right arrow Articles by Skolnick, M. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goldgar, D. E.
Right arrow Articles by Skolnick, M. H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 86, No. 3, 200-209, February 2, 1994
© 1994 Oxford University Press

A Large Kindred With 17q-Linked Breast and Ovarian Cancer: Genetic, Phenotypic, and Genealogical Analysis

David E. Goldgar, Patty Fields, Cathryn M. Lewis, Thao D. Tran, Lisa A. Cannon-Albright, John H. Ward, Jeff Swensen, Mark H. Skolnick*,

Genetic Epidemiology Group, Department of Medical Informatics Salt Lake City
Division of Hematology/Oncology, Department of Internal Medicine), University of Utah Salt Lake City

*Correspondence to: David E. Goldgar, ph.D., Genetic Epidemiology, 420 Chipeta Way, #180, Salt Lake City. UT 84108.

BACKGROUND: Mutation of a specific, but as yet unidentified, gene BRCA1 on chromosome 17q results in increased susceptibility to breast and ovarian cancer. It is important to know the effects of this gene in terms of the age-specific risks of these cancers and the potential interaction of this gene with other known risk factors.

PURPOSE: We performed detailed studies on a large multi-generational family, in which there is known 17q-linked breast and ovarian cancer, in order to characterize the effects of the BRCA1 mutation on development of breast and ovarian cancer.

METHODS: Data from the Utah Population Database were used to identify a family (identified as K2082) with a cluster of premenopausal breast cancer and ovarian cancer at any age. Blood samples from 195 members of the family were obtained and these individuals were genotyped for a series of four chromosome 17q polymorphic markers. Information on reproductive history, cancer incidence and treatment, and lifestyle factors was collected on 72 women in the family by questionnaire or through contact with living relatives.

RESULTS: Odds in favor of linkage of breast and ovarian cancer in this family to the BRCA1 region of chromosome 17Q are greater than 108to 1. The estimated risks for breast or ovarian cancer because of the BRCA1 mutation in this family are 40% by age 50 years and 90% by age 70. No differences between affected and unaffected older BRCA1 gene carriers were observed for a number of known epidemiologic risk factors for these cancers. The gender of the parent from whom the mutant BRCA1 allele was inherited was significantly associated with phenotypic expression (P =.04). A recombinant which places BRCA1 distal to the marker Mfd191 was observed.

CONCLUSIONS: Women with the BRCA1 mutation are at increased risk of developing breast and ovarian cancer. In our study population, the mutation appears to confer a lower risk of cancer at younger ages than found in previous studies. Continued interaction with family K2082 will be useful in longitudinal follow-up studies and in studies of the psychosocial implications of providing DNA diagnosis of BRCA1. [J Natl Cancer Inst 86:200–209, 1994]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
A. M. Stroup and K. R. Smith
Familial Effects of BRCA1 Genetic Mutation Testing: Changes in Perceived Family Functioning
Cancer Epidemiol. Biomarkers Prev., January 1, 2007; 16(1): 135 - 141.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
K. R. Smith, L. Ellington, A. Y. Chan, R. T. Croyle, and J. R. Botkin
Fertility Intentions Following Testing for a BRCA1 Gene Mutation
Cancer Epidemiol. Biomarkers Prev., May 1, 2004; 13(5): 733 - 740.
[Abstract] [Full Text] [PDF]

Home page
 Genome ResHome page
D. Cozma, L. Lukes, J. Rouse, T. H. Qiu, E. T. Liu, and K. W. Hunter
A Bioinformatics-Based Strategy Identifies c-Myc and Cdc25A as Candidates for the Apmt Mammary Tumor Latency Modifiers
Genome Res., June 1, 2002; 12(6): 969 - 975.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
K. R. Smith, J. A. West, R. T. Croyle, and J. R. Botkin
Familial Context of Genetic Testing for Cancer Susceptibility: Moderating Effect of Siblings' Test Results on Psychological Distress One to Two Weeks after BRCA1 Mutation Testing
Cancer Epidemiol. Biomarkers Prev., April 1, 1999; 8(4): 385 - 392.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
Y Miki, J Swensen, D Shattuck-Eidens, P. Futreal, K Harshman, S Tavtigian, Q Liu, C Cochran, L. Bennett, W Ding, et al.
A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1
Science, October 7, 1994; 266(5182): 66 - 71.
[Abstract] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.